A crucial role of HMGB1 in orofacial and widespread pain sensitization following partial infraorbital nerve transection
A crucial role of HMGB1 in orofacial and widespread pain sensitization following partial infraorbital nerve transection
复制标题
HMGB1 在部分眶下神经横断后口面部和广泛疼痛敏化中的关键作用
DOI:
10.1016/j.bbi.2020.05.020
复制
发表时间:
2020-08-01
影响因子:
15.1
通讯作者:
Zhang, Shi-Hong
中科院分区:
文献类型:
--
作者:
Hu, Ting-Ting;Yu, Jie;Zhang, Shi-Hong
Clinical studies show that orofacial pain, such as trigeminal neuropathic pain, often spreads to adjacent or contralateral symmetrical area (mirror-image pain), even to distant body regions (widespread pain)(Türp et al., 1998, Sipilä et al., 2005). Widespread pain is more persistent than the pain in the orofacial area and is associated with more sensory and affective distress (Krause et al., 1989, Toomey et al., 1984). Recently, we reported that partial infraorbital nerve transection (p-IONX) in mice induces long-range spread of hypersensitivity from the orofacial region to distant body parts, which is accompanied with rostral-caudal transmission of central sensitization and microglia activation along the spinal cord (Zhang et al., 2016). Subsequently, we found that spinal TLR4 signaling participates in the spread of tactile allodynia but not thermal hyperalgesia (Hu et al., 2018). These studies suggest that microglia and TLR4-related neuroinflammation in the spinal cord contribute to the spread of pain sensitization, shedding some light on the pathophysiological mechanism of widespread hypersensitivity. However, pivotal factors involved in the spread of spinal neuroinflammation remain to be identified.High mobility group box 1 (HMGB1) is a highly conserved non-histone nuclear protein and belongs to the damage-associated-molecular-pattern (DAMP) family. HMGB1 is usually located in the nucleus and participates in regulating chromatin structure and gene transcription (Tsung et al., 2014). Under certain conditions, HMGB1 is either passively released from necrotic cells or actively secreted from alive but “stressed” cells after being translocated into the cytoplasm. In the central nervous system (CNS), the cellular source of HMGB1 involves glias and neurons and the release pattern from these cells is temporally differential, implying the complexity of its action (Sun et al., 2015). As an alarmin, the extracellular HMGB1 is believed to activate innate and adaptive immunity and drives host inflammatory responses via interacting with multiple receptors, including the receptor for advanced glycation endproducts (RAGE), toll-like receptor (TLR) 2 and TLR4, as well as other receptors (Lotze and Tracey, 2005, Bertheloot and Latz, 2017). It has been recognized that HMGB1 in the CNS plays important roles in a variety of diseases such as ischemic or traumatic brain injury, multiple sclerosis and neuropathic pain, and may serve as a potential therapeutic target (Singh et al., 2016, Agalave and Svensson, 2015, Laird et al., 2014).